FDA Moved a Class of Cancer Tests From PMA to 510(k). Fewer Than Five Parties Commented.
The order moves these tests from PMA to 510(k). One special control was deleted, and the predicate chain is where the change compounds.
DealPulse Signal
The Beats
Analysis
The Briefs
FDA Moved a Class of Cancer Tests From PMA to 510(k). Fewer Than Five Parties Commented.
Canada Moved Two Cancer Drugs Forward in One Week. Neither Went the Normal Route.
In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part
The Number Everyone Will Quote About European Launches Rests on Eleven Products
Singapore Approved Both Blenrep Combinations. Korea Reimbursed Only the One With Survival Data.